These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7303717)

  • 1. The metabolism of canrenone in vitro by rat liver preparations.
    Boreham DR; Vose CW; Palmer RF; Slater TF; Cheeseman K
    Xenobiotica; 1981 Apr; 11(4):231-40. PubMed ID: 7303717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ring D oxygenated Spirolactones. Characterization of human metabolic product of spironolactone.
    Chinn LJ; Brown EA; Mizuba SS; Karim A
    J Med Chem; 1977 Mar; 20(3):352-5. PubMed ID: 845867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue distribution of 3H-canrenoate potassium in rabbits.
    Finn AM; Brown R; Sadée W
    J Pharm Sci; 1977 Feb; 66(2):275-7. PubMed ID: 839430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difference in metabolic profile of potassium canrenoate and spironolactone in the rat: mutagenic metabolites unique to potassium canrenoate.
    Cook CS; Hauswald CL; Schoenhard GL; Piper CE; Patel A; Radzialowski FM; Hribar JD; Aksamit W; Finnegan P; Bible RH
    Arch Toxicol; 1988 Jan; 61(3):201-12. PubMed ID: 3355365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical structure and aldosterone receptor affinity of canrenoate-potassium metabolites in rabbits.
    Finn AM; Finn C; Sadée W
    Res Commun Chem Pathol Pharmacol; 1976 Dec; 15(4):613-25. PubMed ID: 1005910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
    Cheng SC; Suzuki K; Sadee W; Harding BW
    Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of canrenone after oral administration of spironolactone and intravenous injection of canrenoate-K in healthy man.
    Krause W; Karras J; Seifert W
    Eur J Clin Pharmacol; 1983; 25(4):449-53. PubMed ID: 6653638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a simple fluorometric method on absorption of canrenone.
    Radó JP; Szende L; Takó J; Nagy O; Kozma C
    Int J Clin Pharmacol Biopharm; 1976 Mar; 13(2):123-6. PubMed ID: 1254376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Heazlewood V
    Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutathione conjugation of synthetic steroids in isolated rat hepatocytes.
    Higaki J; Matsui T; Ikenishi Y; Hirata M
    Steroids; 1989 Sep; 54(3):345-54. PubMed ID: 2588308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
    DeFrance A; Armbruster D; Petty D; Cooper KC; Dasgupta A
    Ther Drug Monit; 2011 Feb; 33(1):128-31. PubMed ID: 21079546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aspects of the physiologic bioavailability of spironolactone and canrenone].
    Portal A; Gaillot J; Bieder A; Rodary C; Bertharion JJ
    Sem Hop Ther; 1976 Nov; 52(9):465-70. PubMed ID: 1006321
    [No Abstract]   [Full Text] [Related]  

  • 14. Metabolism of spirolactones by the rat testis in vitro.
    Weissenborn U; Erbler HC
    Steroids; 1983 Oct; 42(4):365-88. PubMed ID: 6679944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of some human urinary metabolites of orally administered potassium canrenoate by stable isotope-labeling techniques.
    Vose CW; Boreham DR; Ford GC; Haskins NJ; Palmer RF
    Drug Metab Dispos; 1979; 7(4):226-32. PubMed ID: 39725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do canrenone and 6,7-dihydroxylated derivatives compete with ouabain at the same site on Na,K-ATPase?
    Tal DM; Karlish SJ
    Mol Pharmacol; 1988 Sep; 34(3):245-9. PubMed ID: 2843743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
    Platt D; Abshagen U; Mühlberg W; Horn HJ; Schmitt-Rüth R; Vollmar J
    Arch Gerontol Geriatr; 1984 Jul; 3(2):147-59. PubMed ID: 6476975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new enzyme-linked chemiluminescent immunosorbent digoxin assay is virtually free from interference of spironolactone, potassium canrenoate, and their common metabolite canrenone.
    Dasgupta A; Kang E; Datta P
    J Clin Lab Anal; 2006; 20(5):204-8. PubMed ID: 16960898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone- and canrenone-induced changes in hepatic (Na+,K+)ATPase activity, surface membrane cholesterol and phospholipid, and fluorescence polarization in the rat.
    Miner PB; Sneller M; Crawford SS
    Hepatology; 1983; 3(4):481-8. PubMed ID: 6305816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.